The latest price target for Cadrenal Therapeutics (NASDAQ:CVKD) was reported by HC Wainwright & Co. on November 11, 2024. The analyst firm set a price target for $32.00 expecting CVKD to rise to within 12 months (a possible 114.77% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Cadrenal Therapeutics (NASDAQ:CVKD) was provided by HC Wainwright & Co., and Cadrenal Therapeutics maintained their buy rating.

There is no last upgrade for Cadrenal Therapeutics

There is no last downgrade for Cadrenal Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cadrenal Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cadrenal Therapeutics was filed on November 11, 2024 so you should expect the next rating to be made available sometime around November 11, 2025.

While ratings are subjective and will change, the latest Cadrenal Therapeutics (CVKD) rating was a maintained with a price target of $3.00 to $32.00. The current price Cadrenal Therapeutics (CVKD) is trading at is $14.90, which is within the analyst’s predicted range.